Forcyte Biotechnologies
In a nutshell: many diseases are caused by how much your cells squeeze (asthma, fibrosis, others). We discover drugs that control how much cells squeeze, with ease, to treat disease. We use patented bioMEMS technology to turn cell strength (cells' ability to pull/ squeeze) into a quantifiable metric in drug discovery, to help find better drugs for mechanical diseases. We screen 100,000s of drugs against numerous contractile human cell types to comprehensively map human mechanobiology (the "contractome") and identify promising drug development starting points to deliver novel medicines to treat mechanically-driven diseases including asthma, hypertension, preterm labor, fibrosis, and others.
Vendors
0Third parties this company currently discloses, grouped by function when classified.
No disclosed vendors yet
Vendors appear only once a public disclosure or other published evidence names them.
Customers
0Companies whose current disclosures name this company as a vendor.
No observed customers yet
Customers appear when another company's current disclosure names this company as a vendor.
Potential customers
0Companies using another vendor in one of Forcyte Biotechnologies’s categories, excluding Forcyte Biotechnologies’s observed customers.
No potential customers found
Potential customers appear after Forcyte Biotechnologies has a category assignment and current vendor relationships can be compared.